english.prescrire.org > Spotlight > 100 most recent > Bempedoic acid (Nilemdo°) or bempedoic acid + ezetimibe (Nustendi°) in cardiovascular prevention

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Bempedoic acid (Nilemdo°) or bempedoic acid + ezetimibe (Nustendi°) in cardiovascular prevention

 Marketing Authorisations  Bempedoic acid has been authorised in the European Union, alone or as part of a fixed-dose combination with ezetimibe, for use in primary or secondary cardiovascular prevention, either as monotherapy or in combination with other cholesterol-lowering drugs, when statins are considered insufficiently effective or cannot be used, which is often due to their adverse effects. 
Full article available for download by subscribers

 ©Prescrire 1 March 2026

Source: "Bempedoic acid (Nilemdo°) or bempedoic acid + ezetimibe (Nustendi°) in cardiovascular prevention" Prescrire Int 2026; 35 (279): 61-64. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Statins in primary
cardiovascular prevention?
Little benefit, documented
harms and many
uncertainties regarding
long-term use"
Prescrire Int 2018;
27 (195): 183-190.
Subscribers only